OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
CSN's Cement Unit Sale Could Exceed $2 Billion as Global Giants Circle 
TSMC Posts Record Q1 Profit Fueled by AI Chip Demand 
Apple Wins ITC Ruling, Keeping Blood-Oxygen Feature on Apple Watch 
Japan to Subsidize Sony's Image Sensor Plant in Kumamoto with $380 Million 
Tesla's Terafab: AI Chip Factory Eyes Taiwan's Semiconductor Talent 
Federal Judge Dismisses DOJ Lawsuit Attempting to Block Hawaii's Climate Case Against Oil Giants 
Goldman Sachs FICC Revenue Falls 10% Amid Iran War Market Volatility 
Anthropic CEO Meets Trump Officials to Discuss Powerful New AI Model Mythos 
Australia Extends Fuel Sulphur Relaxation Amid Iran War Supply Disruptions 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
Japan Opens Arms Export Floodgates: New Policy Draws Global Defense Interest 
Pentagon Taps Auto Giants to Supercharge U.S. Weapons Production 
Elliott Investment Takes ~3% Stake in Daikin, Pushes for Buybacks and Strategic Overhaul 
Elon Musk's Terafab Foundry Courts Top Chipmaking Giants for AI Self-Sufficiency Push 
CATL Stock Hits Record High After Q1 2025 Earnings Surge 
NiSource Signs Long-Term Energy Deals with Alphabet and Amazon to Power Indiana Data Centers 
PARSIPPANY, N.J., June 01, 2017 -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that members of its management team are scheduled to present at the Jefferies 2017 Global Healthcare Conference at 1:30 PM ET on Tuesday, June 6, 2017 in New York City.
A live audio webcast of the Pacira presentation can be accessed by visiting the “Investors & Media” section of the company’s website at investor.pacira.com. A replay of the webcast will be archived on the Pacira website for two weeks following the presentation date.
About Pacira
Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) is a specialty pharmaceutical company focused on the clinical and commercial development of new products that meet the needs of acute care practitioners and their patients. The company’s flagship product, EXPAREL® (bupivacaine liposome injectable suspension), indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia, was commercially launched in the United States in April 2012. EXPAREL and two other products have successfully utilized DepoFoam®, a unique and proprietary product delivery technology that encapsulates drugs without altering their molecular structure, and releases them over a desired period of time. Additional information about Pacira is available at www.pacira.com.
Company Contact: Pacira Pharmaceuticals, Inc. Susan Mesco (973) 451-4030 [email protected]
